Instil Bio Inc (TIL)
65.62
-2.74
(-4.01%)
USD |
NASDAQ |
Sep 27, 16:00
65.80
+0.18
(+0.27%)
After-Hours: 20:00
Instil Bio SG&A Expense (TTM): 45.94M for June 30, 2024
SG&A Expense (TTM) Chart
Historical SG&A Expense (TTM) Data
Date | Value |
---|---|
June 30, 2024 | 45.94M |
March 31, 2024 | 46.76M |
December 31, 2023 | 47.55M |
September 30, 2023 | 49.59M |
June 30, 2023 | 54.64M |
March 31, 2023 | 60.34M |
December 31, 2022 | 62.24M |
September 30, 2022 | 60.50M |
Date | Value |
---|---|
June 30, 2022 | 57.47M |
March 31, 2022 | 54.44M |
December 31, 2021 | 48.31M |
September 30, 2021 | 44.36M |
June 30, 2021 | 33.26M |
March 31, 2021 | 21.46M |
December 31, 2020 | 14.38M |
SG&A Expense Definition
SG&A expense (short for Selling, General and Administrative expense) is a line item on the income statement, though sometimes sales and marketing expenses are reported separately from general and administrative expenses.
SG&A Expense (TTM) Range, Past 5 Years
14.38M
Minimum
Dec 2020
62.24M
Maximum
Dec 2022
46.75M
Average
48.31M
Median
Dec 2021
SG&A Expense (TTM) Benchmarks
Merck & Co Inc | 10.54B |
BioCardia Inc | 3.965M |
Zevra Therapeutics Inc | 43.01M |
PetIQ Inc | 208.04M |
SeaStar Medical Holding Corp | 8.285M |